Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
56.6M
-
Number of holders
-
60
-
Total 13F shares, excl. options
-
32.4M
-
Shares change
-
+1.82M
-
Total reported value, excl. options
-
$523M
-
Value change
-
+$27.8M
-
Number of buys
-
33
-
Number of sells
-
-19
-
Price
-
$16.15
Significant Holders of Design Therapeutics, Inc. - Common Stock, par value $0.0001 per share (DSGN) as of Q1 2022
63 filings reported holding DSGN - Design Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2022.
Design Therapeutics, Inc. - Common Stock, par value $0.0001 per share (DSGN) has 60 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 32.4M shares
of 56.6M outstanding shares and own 57.19% of the company stock.
Largest 10 shareholders include Cormorant Asset Management, LP (5.16M shares), BlackRock Inc. (3.15M shares), Logos Global Management LP (2.8M shares), CITADEL ADVISORS LLC (2.53M shares), EcoR1 Capital, LLC (2.37M shares), Avoro Capital Advisors LLC (2.22M shares), RA CAPITAL MANAGEMENT, L.P. (2.19M shares), VANGUARD GROUP INC (1.87M shares), BAKER BROS. ADVISORS LP (1.44M shares), and JANUS HENDERSON GROUP PLC (1.12M shares).
This table shows the top 60 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.